Sally Kohn: I completely agree that the incentives don't really seem to be aligned. You know, what you typically hear or read in the news is that SPACs are risky speculative investments where you can lose a lot of money. There are actually very few SPACs that have zero revenue and if they are, they're typically SPACs more like drug development, which you also see in IPOs. She says it's a mistake not to look at the aftermarket as a potential value opportunity but there'll be a lot of stones you have to turn over before you may find one.

Get the Snipd
podcast app

Unlock the knowledge in podcasts with the podcast player of the future.
App store bannerPlay store banner

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode

Save any
moment

Hear something you like? Tap your headphones to save it with AI-generated key takeaways

Share
& Export

Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode